Onconova Gets up to $565M in Phase III MDS Baxter Deal
BioWorld Today Contributing Writer
Onconova Therapeutics Inc.'s deal with Baxter International Inc. for European rights to rigosertib for myelodysplastic syndromes (MDS) and pancreatic cancer, worth up to $565 million, tops off a string of agreements over the past few years that leaves the company with full U.S. ownership of the late-stage compound.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST